Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]

£787.5K GBP

Funder	National Institute for Health Research
Recipient Organization	The University of Sheffield
Country	United Kingdom
Start Date	Jan 13, 2021
End Date	Feb 15, 2022
Duration	398 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR131960`

Grant Description

To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating untreated, locally recurrent inoperable or metastatic, triple negative breast cancer.